Coherus Oncology, Inc. Common Stock

CHRSNASDAQ • USD
0.51 USD
↘ 0.02 (3.73%)AT CLOSE (03:59 PM EST)
0.51
↘ 0.00 (0.18%)
POST MARKET (AS OF 04:14 PM EST)
Post Market
AS OF 04:14 PM EST
0.51
↘ 0.00 (0.18%)
🔴Market: CLOSED

Coherus Oncology, Inc. Common Stock (CHRS) trades at $0.51 per share. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". This is driven by a concerning Altman Z-Score in the distress zone, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest CHRS is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Nov 16, 2026.

Open?$0.51
High?$0.53
Low?$0.48
Prev. Close?$0.53
Volume?3.6M
Avg. Volume?2.2M
VWAP?$0.50
Rel. Volume?1.68x
Bid / Ask
Bid?$0.50 × 100
Ask?$0.51 × 2.0K
Spread?$0.01
Midpoint?$0.51
Valuation & Ratios
Market Cap?78.8M
Shares Out?154.5M
Float?130.4M
Float %?84.4%
P/E Ratio?N/A
P/B Ratio?3.12
EPS?-$0.88
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
Employees
145
Market Cap
81.2M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2014-11-06
Address
C/O DENNIS M. LANFEAR
REDWOOD CITY, CA 94065
Phone: (650) 649-3530
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
0
Momentum?
77
Short Sent.?
34
Piotroski F-Score?3/9Weak
Altman Z-Score?-14.07Distress
Confidence?48%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?9.75%Elevated
Short Interest?12.7M
Days to Cover?8.2
Free Float130.4M
Avg Daily Volume1.6M
Settlement Date2026-10-30
Financial Health
Current Ratio?1.51Adequate
Quick Ratio?1.45Adequate
Cash Ratio?0.71Adequate
Debt/Equity?2.08High
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
92/100
P/E?
N/A▾
P/B?
Peers
100
S&P
54
3.12FAIR▾
P/S?
Peers
100
S&P
79
1.47CHEAP▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.5CHEAP▾
EV/Sales?
Peers
100
S&P
85
1.45CHEAP▾
Returns & Efficiency
ROE?
S&P
3
-538.4%WEAK▾
ROA?
S&P
3
-79.5%WEAK▾
Cash Flow & Enterprise
FCF?$-652392000
Enterprise Value?$77.9M
Fundamentals ratios updated end of day